SCHEMBL1449412

SCHEMBL1449412

COc1ccc(-c2ccc(N3CC4CCCCC(C3)N4C)nn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.46
HTR3A P46098 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
HRH3 Q9Y5N1 2/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SCD O00767 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
PKM P14618 1/20 0.42
TP53 P04637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676801 0.97 CHRNA7 (0.46) CHRNA7HTR3ACHRNB4CHRNA3HRH3
SCHEMBL3390767 0.95 CHRNA7 (0.48) CHRNA7HTR3ACHRNB4CHRNA3NPC1
SCHEMBL1449308 0.86 CHRNA7 (0.45) CHRNA7HTR3ACHRNB4CHRNA3NPC1
SCHEMBL3388698 0.84 SCD (0.49) CHRNA7HTR3ACHRNB4CHRNA3HRH3
SCHEMBL1449402 0.84 CHRNA7 (0.64) CHRNA7HTR3ACHRNB4CHRNA3
SCHEMBL2678504 0.83 CHRNA7 (0.45) CHRNA7HTR3ACHRNB4CHRNA3NPC1
SCHEMBL2677317 0.82 ACACB (0.49) CHRNA7HTR3ACHRNB4CHRNA3SCD
SCHEMBL2678166 0.82 SCD (0.48) CHRNA7HTR3ACHRNB4CHRNA3SCD
SCHEMBL2677926 0.82 TP53 (0.43) CHRNA7HTR3ACHRNB4CHRNA3NPC1
SCHEMBL2676639 0.82 CHRNA7 (0.64) CHRNA7HTR3ACHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910578-B2 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use NEUROSEARCH A/S (DK) 2011-03-22 US disclosed
US-20090099153-A1 NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE ANIONA APS (DK) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099153-A1 NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE CHRNA10, CHRNA7, CHRNA3 CHRNA7 2/4885HTR3A 226/4885CHRNB4 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.